Clinical Trial

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-04-16; most recent amendment 2025-08-11.
Trial Details
NCT Number NCT06375733
Lead Sponsor Genfleet Therapeutics (Shanghai) Inc.
Conditions Large B-cell Lymphoma
Enrollment 51 participants
Start Date 2024-03-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-12